摘要 |
The present invention relates to the use of DC-HIL and fragments and variants thereof to selectively target toxins to activated T-cells expressing a unique form of syndecan-4 that is not found on other cells. Thus, the toxin is delivered only to activated T-cells, and not to other syndecan-4 expressing cells. Such toxin-DC-HIL conjugates are useful in the treatment of T-cell inflammatory disorders such as dermatitis, autoimmune disease, and graft rejection, as well as T-cell lymphomas.
|